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We appreciate Fitzmaurice and colleagues’ acknowledgement of the excellent 
design, execution and findings of the LIBERATE Study showing very meaningful 
benefits of Zephyr Valves in patients with severe emphysema
1
. Successful 
occlusion and reduction of target lobar volume allows healthier tissue to 
expand/better function and these volume shifts can lead to pneumothorax in 
some patients. There are various ways to address this reality.   Fitzmaurice et al. 
report their limited single center experience in placing prophylactic chest tubes in 
all 8 patients that they treated with Zephyr valves for advanced emphysema. 
Although 34.4% of the 128 patients treated with Zephyr Valves within LIBERATE 
developed a pneumothorax, not all patients required a chest tube; 17% of those 




Subjecting all patients who undergo Zephyr valve placement with chest tube 
placement may not be advisable since chest tube placement is not without 
morbidity and mortality.  Chest tube placement has been reported to have early 
and late complication rates of 3% and 8%, respectively, that includes pleural and 
chest wall bleeding, infection, patient discomfort, perforation of major 
intrathoracic organs and unintentional intra-parenchymal lung placement
2
. 
Additionally, in the COPD patient population, errant anterior mediastinal 
placement in the hyperinflated chest has been reported to cause contralateral 
pneumothorax
3
. We have identified and reported patients who are most likely to 
present with significant challenges should they experience a pneumothorax, 
specifically patients in whom the most diseased lobe is not treated, AND the non-
treated contralateral lung destruction score is >60%
1
. Consideration of placement 
of a chest tube prophylactically may be most appropriate in these “high-risk” 
patients in whom the benefit to risk is more attractive versus placing them in 
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every patient.  Maximizing the benefit to risk profile for Zephyr Valve treatment 
begins with proper patient selection i.e. those with little to no collateral 
ventilation (determined with StratX® QCT and/or Chartis®) and physician 
assessment for post-procedure management ranging from prophylactic chest 
tube placement versus the need for closer observation and duration of hospital 
stay. Future work and investigation as illustrated by Fitzmaurice and colleagues 
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